Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is a target of several immunotherapies such as Tremelimumab and Ipilimumab, already included in clinical trials for BC patients [31]. This evidence concerns the gene CTLA4 and breast cancer.